Sensible Biotechnologies
Biotechnology
$19.5Mtotal raised · 3 rounds on record
$13.5Mlatest round · Venture round · Aug 2026 · 2 mo ago
6backers · Y Combinator, Amino Collective
50+team · employees, estimated range
Overview
THE FIRST CELL-BASED mRNA THERAPEUTICS PLATFORM. Synthetic mRNA has reached its limits. Our cell-based mRNA design and manufacturing platform enables pure, low immunogenicity mRNA that unlocks a new era of design-based biology.
Funding and backers
Total raised
$19.5M
3 rounds on record
Latest round
$13.5M
Venture round · Aug 2026 · 2 mo ago
Team
51-200
employees, estimated range
Backers
6
Y Combinator, Amino Collective
The money's age
Fresh money
2 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 17
Raised a round Venture round $13.5M · SEC Form D
Jul 9, 2025
Partnership Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform · YahooFinance
Apr 6, 2023
Raised a round Pre-Seed $4.2M
Apr 4, 2023
Partnership Sensible Biotechnologies Partners with Ginkgo to Develop Novel mRNA Manufacturing Platform · GEN - Genetic Engineering and Biotechnology News
Apr 3, 2023
Partnership Sensible Biotechnologies And Ginkgo Bioworks Announce Partnership To Make In Vivo RNA To Unlock The Promise Of RNA Therapeutics · forbes.com
Jan 31, 2023
Incorporated SENSIBLE BIOTECHNOLOGIES LIMITED · Companies House
Jun 2021
Went through Y Combinator
2021
Founded
Tractionpublic signals, read monthly
Web presence
top 2%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Aug 2026 | $13.5M | — | SEC Form D |
| Pre-Seed | Apr 2023 | $4.2M | — | wgno.com |
| Venture round | Feb 2023 | $1.8M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Sensible Biotechnologies, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Marian KupculakExecutive Officer, DirectorSEC Form D
Miroslav GasparekExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Y Combinator Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Gearbox Biosciences provides stable template plasmids for long poly(A) mRNA therapeutics, alongside antibiotic-free plasmid and protein…
Elevated mRNA for transformative medicines. mRNA has already changed medicine. But the next generation of mRNA medicines – therapies that…
We develop transformative mRNA therapies by leveraging our ground-breaking proprietary delivery technology, machine learning and superior…
Next-Generation mRNA-Based Biological Crop Protection. PreviSAR is a next-generation mRNA-based plant defense inducer that primes the…
Primrose Bio develops and commercializes manufacturing technologies that close gaps in biologics, mRNA and vaccine production.
Amptiv is building a programmable chemical control layer for mRNA. Explore our post-synthesis chemistry platform and TailX™ early access.
Visa sponsorship
A-rated
Sponsor licence
Skilled Worker
Visa route
0
Open roles in United Kingdom
In the register as Sensible Biotechnologies Limited, Oxford
Other sponsors in the same field
Plasmidsaurus 
L.E.K. Consulting 
Sygnature Discovery 
Apoha
Alert me
UK Home Office · checked Nov 12, 2026 · Visa details by country
People
Marian Kupculak
Executive Officer, Director
Miroslav Gasparek
Executive Officer, Director
Joel Schoppig
Director
Vishal Gulati
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Amino CollectiveVia a fund
OTB VenturesVia a fund
Kaya VCVia a fund
BlueYard CapitalVia a fund
Backed VCVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform
AUBAGNE, France & BRATISLAVA, Slovakia, July 09, 2025--Sartorius Stedim Biotech and Sensible Biotechnologies are scaling up a unique cell-based manufacturing platform for clinical-grade therapeutic mRNA.
Read more
Report
Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More Than 90% with AI Platform Built on NVIDIA Technology
BOSTON, June 12, 2025--Sensible Biotechnologies are accelerating the development of their cell-based platform for next-generation mRNA medicines with NVIDIA AI.
Read more
Report
mRNA Platform Company Sensible Biotechnologies Secures $4.2 Million
mRNA platform company Sensible Biotechnologies has announced a $4.2 million pre-seed round to accelerate the development of its cell-based platform for cost-efficient manufacturing of high-quality mRNA.
Read more
Report
Sensible Biotechnologies Raises $4.2mn in a Pre-Seed Financing Round to Revolutionize mRNA Manufacturing
Read more
Report
Sensible Biotechnologies Partners with Ginkgo to Develop Novel mRNA Manufacturing Platform
mRNA technology has the potential to help develop many life-saving therapeutics and vaccines.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Oxford
United Kingdom
HQ
50-200 est. staff